Roche pushes back Spark tender a third time. Will it close the deal on time—or ever?

14th May 2019 Uncategorised 0

Roche has said a delay in the U.S. regulatory review of its $4.3 billion takeover of Spark Therapeutics is “not unusual.” But a third delay is anything but normal.

More: Roche pushes back Spark tender a third time. Will it close the deal on time—or ever?
Source: fierce